Godrej Agrovet Q3 Revenue Up 11%, PBT Soars 23%; Strategic Review Looms

AGRICULTURE
Whalesbook Logo
AuthorAditi Singh|Published at:
Godrej Agrovet Q3 Revenue Up 11%, PBT Soars 23%; Strategic Review Looms
Overview

Godrej Agrovet posted an 11% YoY revenue increase and 23% PBT growth in Q3 FY26. Strong contributions from Animal Feed, Vegetable Oil, and Godrej Foods' margin expansion drove performance. Astec Life Sciences turned profitable. Creamline Dairy faced margin pressure from rising milk costs. A strategic review for value unlocking is underway, with details expected in early April.

📉 The Financial Deep Dive

The Numbers:
Godrej Agrovet Limited reported a strong third quarter for fiscal year 2026 (Q3 FY26), with consolidated revenues growing by 11% year-on-year. While specific consolidated revenue figures were not disclosed, the company announced that profit before tax (before exceptional items) accelerated by 23% year-on-year. For the nine months ended December 31, 2025 (9MFY26), consolidated revenues stood at ₹7,900 crores, an increase of 9% year-on-year. Profit before tax (excluding non-recurring and exceptional items) for the nine-month period grew by 17% year-on-year to ₹482 crores.

The Quality:
Profitability was bolstered by disciplined margin expansion and operational efficiencies across key business verticals.

  • Animal Feed: Witnessed strong volume-led growth, with overall volumes up 12% year-on-year in Q3 FY26. Cattle feed volumes surged 21% YoY, now constituting 54% of segment volumes. Segment results grew 17% YoY, and EBIT per metric ton improved to ₹2,020 from ₹1,937 in the prior year quarter.
  • Vegetable Oil: Delivered stellar performance, with segment revenue growing 27% YoY and segment results up 25% YoY. This was driven by improved Fresh Fruit Bunch (FFB) arrivals and an all-time high Oil Extraction Ratio (OER) of 21% in Q3 FY26. The company is expanding oil palm plantations, adding 15,000 hectares in 9MFY26.
  • Crop Protection: Reported 37% YoY revenue growth, driven by higher salience of generics and specialty products. However, segment results remained flat year-on-year, impacted by unseasonal rains and cyclones.
  • Astec Life Sciences: Showed a strong recovery with 33% YoY revenue growth. The segment turned EBITDA positive at ₹5 crores for the quarter, a significant turnaround from a loss last year, supported by higher volumes and improved gross margins.
  • Creamline Dairy: Recorded a modest 3% YoY revenue growth, but profitability faced pressure. EBITDA declined to ₹11 crores, and margins softened to 3%, primarily due to higher milk procurement costs.
  • Godrej Foods: Delivered stable revenues of ₹215 crores, with EBITDA growing 51% YoY to ₹17 crores and margins expanding to 8%. Branded salience rose to 81%.

The Grill:
Management indicated that a comprehensive strategic review is in its final stages, aimed at value unlocking across its diverse businesses. Clear choices regarding business prioritization, capital allocation, and growth strategies are being made. An announcement detailing these decisions, incorporating market attractiveness and 'right to win' filters, is expected around early April.

🚩 Risks & Outlook

Specific Risks:

  • Creamline Dairy faces continued volatility in milk procurement costs due to weather patterns, although management believes its direct farm procurement network offers a buffer.
  • The Crop Protection business's performance can be susceptible to adverse weather conditions impacting volumes.
  • Execution risks associated with commissioning the new pet food plant and the downstream refinery for the Vegetable Oil business.

The Forward View:
Investors will closely monitor the strategic review announcement in early April, which is expected to clarify capital allocation priorities and business focus. Long-term growth prospects remain strong for the Vegetable Oil business, with an anticipated 12-15% FFB tonnage growth CAGR. Astec Life Sciences is targeting EBITDA breakeven for FY26 and projects approximately 20% revenue growth for FY26. Godrej Foods aims to evolve into a pure-play branded retail organization within five years. The pet food plant is slated for commissioning in about a month, and the triazole business within Astec is showing signs of recovery.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.